Emine Gulsen Gunes1,2, Steven T Rosen1,2, Christiane Querfeld2,3. 1. Department of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Medical Center. 2. Beckman Research Institute. 3. Division of Dermatology, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Abstract
PURPOSE OF REVIEW: This article focuses on the immunosuppressive impact of myeloid-derived suppressor cells (MDSCs) and the potential clinical implications in hematological malignancies. RECENT FINDINGS: MDSCs play a critical role in the regulation of the immune response in cancer. They inhibit activation of adaptive immune response and as a result foster the growth of the malignancy. Recent studies have shown that MDSCs serve as prognostic biomarkers and as targets for cancer immunotherapy. Preclinical and clinical studies have identified new approaches to deplete MDSC populations and inhibit MDSC function with combination immunomodulatory therapies including chemotherapeutic agents with immune checkpoint-directed treatment. SUMMARY: A broad spectrum of publications indicate that direct targeting of MDSCs may abrogate their protumorigenic impact within the tumor microenvironment through activation of the adaptive immune response.
PURPOSE OF REVIEW: This article focuses on the immunosuppressive impact of myeloid-derived suppressor cells (MDSCs) and the potential clinical implications in hematological malignancies. RECENT FINDINGS: MDSCs play a critical role in the regulation of the immune response in cancer. They inhibit activation of adaptive immune response and as a result foster the growth of the malignancy. Recent studies have shown that MDSCs serve as prognostic biomarkers and as targets for cancer immunotherapy. Preclinical and clinical studies have identified new approaches to deplete MDSC populations and inhibit MDSC function with combination immunomodulatory therapies including chemotherapeutic agents with immune checkpoint-directed treatment. SUMMARY: A broad spectrum of publications indicate that direct targeting of MDSCs may abrogate their protumorigenic impact within the tumor microenvironment through activation of the adaptive immune response.
Authors: Isabel Poschke; Dimitrios Mougiakakos; Johan Hansson; Giuseppe V Masucci; Rolf Kiessling Journal: Cancer Res Date: 2010-05-18 Impact factor: 12.701
Authors: Yumeng Mao; Dhifaf Sarhan; André Steven; Barbara Seliger; Rolf Kiessling; Andreas Lundqvist Journal: Clin Cancer Res Date: 2014-06-06 Impact factor: 12.531
Authors: Eric Tartour; H Pere; B Maillere; M Terme; N Merillon; J Taieb; F Sandoval; F Quintin-Colonna; K Lacerda; A Karadimou; C Badoual; A Tedgui; W H Fridman; S Oudard Journal: Cancer Metastasis Rev Date: 2011-03 Impact factor: 9.264
Authors: Güllü Topal Görgün; Gregory Whitehill; Jennifer L Anderson; Teru Hideshima; Craig Maguire; Jacob Laubach; Noopur Raje; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson Journal: Blood Date: 2013-01-15 Impact factor: 22.113